Live SpaceX Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Neuphoria Therapeutics Inc.

Get SEC filing alerts via email and in your feed for Neuphoria Therapeutics Inc.

NEUP

Neuphoria Therapeutics Inc.

About Neuphoria Therapeutics Inc.

Bionomics Limited is an Australian clinical-stage biopharmaceutical company specializing in novel allosteric modulators of ion channels, primarily targeting the α7 nicotinic acetylcholine receptor for central nervous system disorders. Its lead product, BNC210, is an oral small molecule developed for anxiety and stress-related conditions like PTSD and social anxiety disorder. The company leverages ion channel biology expertise and partnerships to develop treatments addressing unmet medical needs in neuropsychiatric and cognitive disorders.
This description was generated via AI from an annual report. Updated 9 months ago.

Latest SEC Filings from Neuphoria Therapeutics Inc.

1
1
Neuphoria Therapeutics Inc. Neuphoria Therapeutics Reports No Revenue and Significant Losses in Latest 10-Q Filing

Via official filing (AI summary) | about 1 month ago | 0 comments

2
1
Neuphoria Therapeutics Inc. Neuphoria Therapeutics Reports Q2 2026 Financial Results with $1.9M Net Income Turnaround

Via official filing (AI summary) | 4 months ago | 0 comments

3
1
Neuphoria Therapeutics Inc. Neuphoria Therapeutics Reports $9.9 Million Net Loss and Increased R&D Expenses

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Neuphoria Therapeutics Inc. Neuphoria Therapeutics Reports $15.6M Revenue Increase and Improved Net Loss for Fiscal Year Ending June 30, 2025

Via official filing (AI summary) | 9 months ago | 0 comments

5
1
Neuphoria Therapeutics Inc. Neuphoria Therapeutics Reports $15 Million Revenue and $11.3 Million Net Income for Quarter Ending March 31, 2025

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Neuphoria Therapeutics Inc. Neuphoria Therapeutics Reports $662,715 Revenue in Q2 FY2025, Continues to Operate at a Loss

Via official filing (AI summary) | over 1 year ago | 0 comments

7
1
Neuphoria Therapeutics Inc. Bionomics Limited Reports Reduced Net Loss, Decreased Expenses in Q3 2024

Via official filing (AI summary) | over 1 year ago | 0 comments